

#### INTRODUCTION

- Growth hormone (GH) affects many of the metabolic processes carried out by somatic cells, most notably increasing body mass. Overall growth is stimulated by GH therapy; however, the effects are not evenly distributed among protein, lipid and carbohydrate compartments. Specifically, body protein content and bone mass increase, total body fat content decreases, and there is an increase in plasma and liver lipid content due to the mobilization of free fatty acids from peripheral fat stores. Another physiological effect of GH is stimulation of cartilage growth (*Molitch et al 2011*).
- Growth hormone deficiency (GHD) in pediatric patients is a clinical diagnosis that is confirmed by biochemical testing. A patient's growth patterns are compared to the established norms. The clinical manifestations of GHD vary depending on whether a patient has complete or partial deficiency. In complete deficiency, pediatric patients present with early severe growth failure, delayed bone age, central disposition of body fat and very low serum concentrations of GH, insulin-like growth factor-1 (IGF-1) and IGF binding protein-3. These patients are also more prone to hypoglycemia, prolonged jaundice, microphallus in males and giant cell hepatitis. GHD in pediatric patients with partial deficiency may be more difficult to diagnose, as these manifestations may not be as obvious (*Molitch et al 2011*).
- Once a diagnosis of GHD is confirmed in pediatric patients, GH therapy should be initiated and continued until cessation of linear growth. Therapy should be initiated as soon as possible, as evidence demonstrates that growth response is more robust when GH therapy is started at a younger age (*Molitch et al 2011*).
- Several preparations of GH are currently available for use in pediatric patients. Recombinant GH preparations, administered by subcutaneous (SC) injection, are currently the most widely utilized. Due to the variability in individual response to therapy, after initial dosing, the dose of GH is adjusted based on growth response and IGF-1 level. While not universally supported, the therapeutic goal of therapy is to achieve a level of IGF-1 that is slightly higher than average, because growth velocity is typically greatest at these levels. A patient's growth velocity, as compared to a similar population, should also be monitored to determine if the growth response is adequate (*Molitch et al 2011*).
- Possible explanations for an inadequate response to GH therapy include poor adherence, incorrect diagnosis of GHD, subtherapeutic dose of GH, or concurrent mild GH insensitivity. In pediatric patients, GH therapy is typically continued at least until linear growth is nearly complete (eg, decreased to less than 2.5 centimeters per year). At this point, retesting for GHD should occur to determine if GH therapy should be continued into adulthood (*Molitch et al 2011*).
- The majority of pediatric patients with idiopathic, isolated GHD in their childhood have normal GH secretion during late adolescence and young adulthood. In contrast, pediatric patients with genetic GHD, multiple pituitary hormone deficiencies, and/or those with structural defects in the hypothalamic-pituitary region rarely recover the ability to secrete GH as an adult. Therefore, retesting may not be required (*Molitch et al 2011*).
- GHD may also occur in adult patients. Approximately 15% to 20% of adult-onset GHD represents the continuation of childhood-onset GHD into maturity; the remainder is adult-onset acquired from damage to the pituitary gland or hypothalamus. GHD is associated with increased metabolic syndrome, increased cardiovascular morbidity and mortality rates, reduced lean body mass, increased abdominal adiposity, early atherosclerosis, dyslipidemia, coagulation abnormalities, insulin resistance, decreased bone mineral density, and a decreased quality of life (*Reed et al 2013*). The role of GH therapy in adults is not as clear as it is in pediatric patients in whom therapy is required for normal growth. There is evidence to demonstrate that when used in adult patients with GHD, GH therapy increases muscle mass and decreases body fat. Evidence of other potential beneficial effects of GH therapy in adults is not as well established and includes improvement in bone mineral density, sense of well-being, muscle strength, and lipid profile. GH therapy can be considered in adult patients with severe clinical manifestations and unequivocal evidence of GHD due to organic disease of childhood- or adult-onset (*Molitch et al 2011*).
- All of the GH preparations contain somatotropin, otherwise known as recombinant human GH. The various preparations are Food and Drug Administration (FDA)-approved for use in a variety of pediatric conditions associated with a failure in growth, including chronic kidney disease (CKD), Turner syndrome, being born small for gestational age, Prader-Willi syndrome, mutations in the Short Stature Homeobox gene, Noonan syndrome, and idiopathic short stature.

## Therapeutic Class Overview

Title

- The majority of preparations are also indicated for the treatment of GHD in adults. Of note, Serostim is FDA-approved solely for the treatment of human immunodeficiency virus-associated wasting or cachexia in adults, while Zorbtive is approved for the treatment of short bowel syndrome in patients receiving specialized nutritional support. Specific FDA-approved indications for the various GH preparations are outlined in Table 2. All of the available GH preparations are available for SC injection, and there are currently no generics available within the class.
- GH preparations are available in various formulations, and several delivery devices are available. The dosing device may be a factor in patient adherence with the prescribed regimen.
- Medispan Class: Growth Hormones

**Table 1. Medications Included Within Class Review**

Drug	Generic Availability
Genotropin (somatropin)	-
Humatrope (somatropin)	-
Norditropin Flexpro (somatropin)	-
Nutropin AQ (somatropin)	-
Omnitrope (somatropin)	-
Saizen (somatropin)	-
Sersotim (somatropin)	-
Zomacton (somatropin)	-
Zorbtive (somatropin)	-

(Drugs@FDA 2019, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 2019)

### INDICATIONS

**Table 2. Food and Drug Administration Approved Indications**

Indication	Genotropin	Humatrope	Norditropin Flexpro	Nutropin AQ	Omnitrope	Saizen	Sersotim	Zomacton	Zorbtive
Growth failure associated with chronic renal insufficiency before renal transplant				✓					
Growth failure associated with Noonan syndrome			✓						
Growth failure associated with Prader-Willi syndrome	✓		✓		✓				
Growth failure associated with short-stature homeobox-containing gene deficiency		✓						✓	
Growth failure associated with Turner syndrome	✓	✓	✓	✓	✓			✓	
Growth failure in children born small for gestational age	✓	✓	✓		✓			✓	
Growth hormone deficiency	✓	✓	✓	✓	✓	✓		✓	
Idiopathic short stature	✓	✓	✓	✓	✓			✓	

Data as of February 20, 2019 JA-U/

Page 2 of 9

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.

Indication	Genotropin	Humatrope	Norditropin Flexpro	Nutropin AQ	Omnitrope	Saizen	Serostim	Zomacton	Zorbtive
Human immunodeficiency virus-associated wasting or cachexia							✓		
Treatment of short bowel syndrome in patients receiving nutritional support									✓

(Prescribing information: *Genotropin 2016, Humatrope 2016, Norditropin Flexpro 2018, Nutropin AQ 2016, Omnitrope 2016, Saizen 2018, Serostim 2018, Zomacton 2018, Zorbtive 2017*)

- Information on indications, mechanism of action, pharmacokinetics, dosing, and safety has been obtained from the prescribing information for the individual products, except where noted otherwise.

### CLINICAL EFFICACY SUMMARY

- There are limited head-to-head clinical trials comparing different GH preparations to one another.
- Clinical data support the use of GH for the treatment of growth failure associated with chronic renal insufficiency. A meta-analysis of 16 RCTs (N = 809) evaluating the effects of GH in children with CKD found that patients who were treated with GH had a greater increase in mean height velocity (3.88 cm) than those who received either no treatment or placebo after 1 year (*Hodson et al 2012*). A retrospective, matched control cohort study found that long-term therapy with GH (mean 4.2 years) reduced linear growth deceleration in children with CKD and improved final height (*Bizzarri et al 2018*).
- Clinical trials have demonstrated efficacy of GH for the treatment of growth failure in patients with Noonan syndrome. A randomized controlled trial evaluating GH in patients with Noonan syndrome found a positive effect of GH on linear growth. Specifically, there was a significantly greater change in height standard deviation score, and bone maturation was accelerated with GH compared to no treatment. In this trial, data also suggest that once treatment with GH is discontinued, “catch-down” (artificially stimulated growth declines once GH is discontinued) growth can occur (*Noordam et al 2001*). In a follow-up analysis of 29 patients treated with GH for a median of 6.4 years, a total of 22 children reached an adult height in the normal range (*Noordam et al 2008*). In a study of 65 patients enrolled in the National Cooperative Growth Study (NCGS) database, it was found that treatment with GH led to gains over predicted height of 9.2 cm in females and 10.9 cm in males (*Romano et al 2009*).
- Clinical trials have demonstrated the significant benefits of GH in pediatric patients with Prader-Willi syndrome in accelerating growth and in improving body composition. Benefits were also observed in improving bone mineral density, lipid profiles, energy expenditure, strength and agility, and pulmonary function (*Carrel et al 1999, Carrel et al 2004, Festen et al 2008, Lindgren et al 1997, Lindgren et al 1998, Lindgren et al 1999, Myers et al 1999, Myers et al, 2007*). Data from 1 trial suggested that growth velocity declines dramatically once treatment is discontinued (*Lindgren et al 1997*).
- Humatrope demonstrated efficacy in increasing first-year height velocity in patients with Short Stature Homeobox-containing gene deficiency when compared to no treatment ( $p < 0.0001$ ) (*Blum et al 2007*).
- Several clinical trials have demonstrated that GH significantly increases the growth rate of pediatric patients with Turner syndrome. Overall, various dose ranging trials did not consistently demonstrate a superior weight-based GH dosing regimen over another; all doses of GH were beneficial. In addition, data suggested that increases in height are greatest during the first year of therapy (*Baxter et al 2007, Bertrand et al 1996, Massa et al 1995, Nienhuis et al 1993, Sas et al 1999a, Takano et al 1989a, Takano et al 1989b, Takano et al 1989c, Takano et al 1993, Takano 1995, van Pareren et al 2003, van Teunenbroek et al 1996*). A Cochrane Review of 4 randomized controlled trials demonstrated that GH (0.3 to 0.375 mg/kg/week) increased short-term growth in patients with Turner syndrome by approximately 3 cm during the first year of treatment. Despite the increase, the final height achieved was still below the normal range (*Baxter et al 2007*).
- For the treatment of growth failure in pediatric patients born small for gestational age, clinical trials have demonstrated the significant benefits of GH on increasing growth rates (*Arends et al 2003, Bannink et al 2010, Boguszewski et al 1998, Bozzola et al 2004, Chatelain et al 1994, De Schepper et al 2008, de Zegher et al 1996, de Zegher et al 2005, Jung et al 2009, Maiorana et al 2009, Sas et al 1999b*). Data from individual clinical trials and 3 meta-analyses found

that response to GH therapy is dose-dependent, and higher doses of GH resulted in additional gain (*de Zegher et al 1996, de Zegher et al 2005*).

- Treatment with GH has been shown to increase height velocity in both prepubertal and pubertal pediatric patients with GHD (*Coelho et al 2008, Cohen et al 2002, de Muinck Keizer-Schrama et al 1992, Kriström et al 2009, MacGillivray et al 1996, Mauras et al 2000, Romer et al 2009, Sas et al 2010, Shih et al 1994, Wilson et al 1985*). Two head-to-head trials demonstrated no differences in safety and efficacy with different GH preparations for the treatment of pediatric GHD. One of the trials compared 3 GH preparations (Genotropin, Humatrope, and Saizen), while the second evaluated 2 preparations (Genotropin and Omnitrope) (*Romer et al 2009, Shih et al 1994*).
- In pediatric patients with idiopathic short stature, somatropin has been shown to increase first-year growth velocity and final height (*Albertsson-Wikland et al 2008, Bryant et al 2007, Deodati et al 2011, Finkelstein et al 2002, Hopwood et al 1993, Kriström et al 2009, van Gool et al 2010, Wit et al 2005*). Additionally, once daily compared to 3 times weekly dosing and higher compared to lower dosing demonstrated a greater increase in growth velocity (*Bryant et al 2007, Finkelstein et al 2002*).
- A systematic review and meta-analysis of 54 placebo-controlled, randomized controlled trials enrolling over 3400 patients found that GH therapy was associated with reduced body fat and increased lean mass in adults with GHD (*Hazem et al 2012*). Eleven of 16 trials that assessed quality of life outcomes reported positive outcomes, but a meta-analysis was not possible. Furthermore, results from meta-analyses and randomized controlled trials have demonstrated that treatment with GH was associated with improved cardiac function and bone mineral density (*Barake et al 2014, Davidson et al 2004, Maison et al 2003*). However, there are currently conflicting data with regard to the effect of GH on cognitive function, quality of life, and exercise capacity (*Arwert et al 2005, Falletti et al 2006, Rubeck et al 2009, Widdowson, 2010*).
- In patients with human immunodeficiency virus-associated wasting, Serostim has been shown to increase body weight, lean body mass, and work output. However, effects on quality of life were variable (*Moyle et al 2004, Schambelan et al 1996*).
- A meta-analysis assessed the safety and efficacy of GH with or without glutamine supplementation for adult patients with short bowel syndrome; 5 studies were included in the review. Human GH with or without glutamine appeared to provide benefit in terms of increased weight (median [MD] 1.66 kg; 95% confidence interval [CI], 0.69 to 2.63;  $p = 0.0008$ ), lean body mass (MD 1.93 kg; 95% CI, 0.97 to 2.9;  $p = 0.0001$ ), energy absorption (MD 4.42 Kcal; 95% CI, 0.26 to 8.58;  $p = 0.04$ ) and nitrogen absorption (MD 44.85 g; 95% CI, 0.2 to 9.49;  $p = 0.04$ ) for patients with short bowel syndrome. One randomized controlled trial which focused on parenteral nutrition (PN) requirements demonstrated decreased PN volume, calories, and number of infusions in patients who received GH with or without glutamine supplementation. Only patients who received GH with glutamine maintained statistically significant PN reductions at 3-month follow-up. The results suggested a positive effect of GH on weight gain and energy absorption. However, after cessation of therapy, the effects returned to baseline in the majority of the trials (*Wales et al 2010*).

## CLINICAL GUIDELINES

- For pediatric patients, treatment guidelines recommend the use of GH therapy with somatropin as a treatment option for children with growth failure associated with any of the following: GHD, GHD in childhood cancer survivors, Noonan syndrome, Turner syndrome, Prader-Willi syndrome, chronic renal insufficiency, born small for gestational age, and short stature homeobox-containing gene deficiency (*Cohen et al 2008, Deal et al 2013, Gravholt et al 2017, Grimberg et al 2016, Ketteler et al 2017, National Kidney Foundation 2009, Sklar et al 2018*). Routine use of GH in every child with idiopathic short stature is not recommended; decisions about GH therapy should take into account physical and psychological burdens as well as risks and benefits (*Grimberg et al 2016*). Guidelines do not prefer one GH agent over another. Choice of preparation should be individualized based on potential advantages and disadvantages of therapy, therapeutic need, and the likelihood of adherence.
- For adult patients, treatment guidelines recommend the use of GH therapy in patients with clinical features suggestive of adult GHD and biochemically proven evidence of adult GHD (*Cook et al 2009*). Therapy should be individualized independent of body weight. The dose of GH should be low initially and gradually increased to the minimally effective dose that normalizes IGF-1 levels without side effects (*Cook et al 2009, Molitch et al 2011*). The 2009 American Association of Clinical Endocrinologists guidelines state that no evidence exists to support any specific GH product over another (*Cook et al 2009*).
- Small studies evaluating the use of GH in short bowel syndrome have yielded conflicting results; methodological differences limit definitive conclusions on the efficacy of GH. In carefully selected patients who are candidates for growth factor treatment, the glucagon-like peptide-2 analog, teduglutide, is recommended as first-line therapy (*Pironi et al 2016*).

## SAFETY SUMMARY

- Contraindications to GH products include active malignancy, diabetic retinopathy, hypersensitivity to the agent or any of its excipients, acute critical illness, and use for growth promotion in children with closed epiphyses. Somatropin is also contraindicated in children with Prader-Willi syndrome who are severely obese, have severe respiratory impairment, or have a history of upper airway obstruction or sleep apnea (Genotropin, Humatrope, Norditropin Flexpro, Nutropin AQ, Omnitrope, Saizen, Zomacton).
- Key Warnings/Precautions:
  - Somatropin may contribute to the increased mortality in patients with acute critical illness due to complications from open heart surgery, abdominal surgery, accidental trauma, or respiratory failure.
  - Somatropin may increase progression or recurrence of intracranial neoplasms, particularly meningiomas in patients treated with radiation to the head for their first neoplasm.
  - Undiagnosed or untreated hypothyroidism may impair optimal response to somatropin.
  - Somatropin may decrease insulin sensitivity, and previously undiagnosed diabetes mellitus may be unmasked during treatment.
  - Intracranial hypertension and pancreatitis have been reported with somatropin treatment.
  - Slipped capital femoral epiphyses and scoliosis can occur in pediatric patients.
  - Fluid retention has been associated with somatropin in adult patients.
  - Increases in serum levels of inorganic phosphorous, alkaline phosphatase, parathyroid hormone and IGF-1 may occur.
  - Tissue atrophy may occur when somatropin is SC administered at the same site over a long period of time.
  - Somatropin may reduce serum cortisol levels or unmask central hypoadrenalism in patients at risk for pituitary hormone deficiency.
- Adverse Drug Events: Arthralgia, myalgia, edema, carpal tunnel syndrome, paresthesia, hyperglycemia, headaches, lipoatrophy, and injection site reactions.
- Drug Interactions: Estrogens, glucocorticoids, and insulin or other hypoglycemic agents.

## DOSING AND ADMINISTRATION

**Table 3. Dosing and Administration**

Drug	Available Formulations	Route	Usual Recommended Frequency	Comments
Genotropin (somatropin)	Injection	SC	Weekly dose divided into 6 or 7 injections to Daily	Injections should be rotated to help prevent lipoatrophy.
Humatrope (somatropin)	Injection	SC	Weekly dose divided into 6 or 7 injections to Daily	Injections should be rotated to help prevent lipoatrophy.
Norditropin Flexpro (somatropin)	Injection	SC	Weekly dose divided into 6 or 7 injections to Daily	Injections should be rotated to help prevent lipoatrophy.
Nutropin AQ (somatropin)	Injection	SC	Weekly dose divided into 3 to 7 injections to Daily	Injections should be rotated to help prevent lipoatrophy.
Omnitrope (somatropin)	Injection	SC	Weekly dose divided into 6 or 7 injections to Daily	Injections should be rotated to help prevent lipoatrophy.
Saizen (somatropin)	Injection	SC	Weekly dose divided into 3, 6, or 7 injections to Daily	Injections should be rotated to help prevent lipoatrophy.
Sersotim (somatropin)	Injection	SC	Daily	Injections should be rotated to avoid local irritation.
Zomacton (somatropin)	Injection	SC	Weekly dose divided into 3, 6, or 7 injections to Daily	Injections should be rotated to help prevent lipoatrophy.
Zorbtive (somatropin)	Injection	SC	Daily	Injections should be rotated to help prevent lipoatrophy.  Dosage titration is recommended for fluid retention



Drug	Available Formulations	Route	Usual Recommended Frequency	Comments
				and arthralgia/carpal tunnel syndrome.

See the current prescribing information for full details.

## CONCLUSION

- The safety and efficacy of GH therapy in pediatric patients with growth failure are well established. Treatment guidelines recommend the use of somatotropin as a treatment option for children with growth failure associated with any of the following: GHD, GHD in childhood cancer survivors, Turner syndrome, Prader-Willi syndrome, chronic renal insufficiency, born small for gestational age, and short stature homeobox-containing gene deficiency (*Clayton et al 2007, Cohen et al 2008, Deal et al 2013, Gravholt et al 2017, Grimberg et al 2016, Ketteler et al 2017, National Kidney Foundation 2009, Sklar et al 2018*). Routine use of GH in every child with idiopathic short stature is not recommended; decisions about GH therapy should take into account physical and psychological burdens as well as risks and benefits (*Grimberg et al 2016*). Guidelines do not prefer one GH agent over another. Choice of preparation should be individualized based on potential advantages and disadvantages of therapy, therapeutic need, and the likelihood of adherence.
- For adult patients, treatment guidelines recommend the use of GH therapy patients with clinical features suggestive of adult GHD and biochemically proven evidence of adult GHD. There should be a careful evaluation of the benefits and risks specific to the individual. The 2009 American Association of Clinical Endocrinologists Guidelines state that no evidence exists to support any specific GH product over another (*Cook et al 2009, Fleseriu et al 2016*).
- There are several GH preparations currently available, which all contain somatotropin (recombinant human GH). The various preparations are equally biopotent and have the same natural sequence structure (*Rogol et al 2018*). Differences between products such as device features, dose increments, requirement for reconstitution, and requirement for refrigeration may influence individual patient preferences. All of the available GH preparations are available for SC injection, and there are currently no generics available within the class.
- Common adverse reactions that may be observed with GH therapy include arthralgia, myalgia, edema, carpal tunnel syndrome, paresthesia, hyperglycemia, headaches, lipoatrophy, and injection site reactions.

## REFERENCES

- Albertsson-Wikland K, Aronson AS, Gustafsson J, et al. Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. *J Clin Endocrinol Metab.* 2008;93(11):4342-4350.
- Arends NJT, Boonstra VH, Mulder PGH, et al. GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: three-year results of a randomized, controlled GH trial. *Clin Endocrinol (Oxf).* 2003;59(3):779-787.
- Bannink E, Djurhuus CB, Christensen T, et al. Adult height and health-related quality of life after growth hormone therapy in small for gestational age subjects. *J Med Econ.* 2010;13(2):221-227.
- Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. *J Clin Endocrinol Metab.* 2014;99:852-860.
- Baxter L, Byrant L, Cave CB, Milne R. Recombinant growth hormone for children and adolescents with Turner syndrome. *Cochrane Database Syst Rev.* 2007;(1):CD003887.
- Bertrand AM, Chaussain JL, Job B, et al. Three years of GH treatment in Turner 's syndrome: complex effect of GH dosage on growth parameters. *Clin Endocrinol (Oxf).* 1996;44(6):665-671.
- Bizzarri C, Lonero A, Delvecchio M, et al. Growth hormone treatment improves final height and nutritional status of children with chronic kidney disease and growth deceleration. *J Endocrinol Invest.* 2018;41(3):325-331.
- Blum WF, Crowe BJ, Quigley CA, et al; SHOX Study Group. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial. *J Clin Endocrinol Metab.* 2007;92(1):219-228.
- Boguszewski M, Albertsson-Wikland K, Aronsson S, et al. Growth hormone treatment of short children born small-for-gestational-age: the Nordic Multicentre Trial. *Acta Paediatr.* 1998;87(3):257-263.
- Bozzola E, Lauriola S, Messina MF, et al. Effect of different growth hormone dosages on the growth velocity in children born small for gestational age. *Horm Res.* 2004;61(2):98-102.
- Bryant J, Baxter L, Cave CB, Milne R. Recombinant growth hormone for idiopathic short stature in children and adolescents. *Cochrane Database Syst Rev.* 2007;(3):CD004440.
- Carrel AL, Myers SE, Whitman BY, et al. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. *J Pediatr.* 1999;132(2):215-221.
- Carrel AL, Moerchen V, Myers SE, et al. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. *J Pediatr.* 2004;145:744-749.
- Chatelain P, Job JC, Blanchard J, et al. Dose-dependent catch-up growth after two years of growth hormone treatment in intrauterine growth-retarded children. Belgian and French Pediatric Clinics and Sanofi-Choay (France). *J Clin Endocrinol Metab.* 1994;78(6):1454-1460.

- Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. *J Clin Endocrinol Metab.* 2007;92(3):804-810.
- Coelho R, Brook CG, Preece MA, et al. A randomized study of two doses of biosynthetic human growth hormone on final height of pubertal children with growth hormone deficiency. *Horm Res.* 2008;70(2):85-88.
- Cohen P, Bright GM, Rogol AD, et al; American Norditropin Clinical Trials Group. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. *J Clin Endocrinol Metab.* 2002;87(1):90-98.
- Cohen P, Rogol AD, Deal CL, et al; 2007 ISS Consensus Workshop participants. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Pediatric Endocrinology Workshop. *J Clin Endocrinol Metab.* 2008;93(11):4210-4217.
- Cook DM, Yuen KC, Biller BM, et al; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. *Endocr Pract.* 2009;15(Suppl 2):1-29.
- de Muinck Keizer-Schrama SM, Rikken B, Wynne HJ, et al. Dose-response study of biosynthetic human growth hormone (GH) in GH-deficient children: effects on auxological and biochemical parameters. Dutch Growth Hormone Working Group. *J Clin Endocrinol Metab.* 1992;74(4):898-905.
- De Schepper J, Thomas M, Beckers D, et al. Growth hormone treatment and fat redistribution in children born small for gestational age. *J Pediatr.* 2008;152:327-330.
- de Zegher F, Albertsson-Wikland K, Wilton P, et al. Growth hormone treatment of short children born small for gestational age: meta-analysis of four independent, randomized, controlled, multicentre studies. *Acta Paediatr Suppl.* 1996;417:27-31.
- de Zegher F, Hokken-Koelega A. Growth hormone therapy for children born small for gestational age: height gain is less dose dependent over the long term than over the short term. *Pediatrics.* 2005;115(4):e458-462.
- Deal CL, Tony M, Hyobye C, et al. Growth Hormone Research Society Workshop Summary: Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi Syndrome. *J Clin Endocrinol Metab.* 2013;98:E1072-E1087.
- Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. *BMJ.* 2011;342:c7157.
- Drugs@FDA [database on the Internet]. Rockville (MD): Food and Drug Administration (US), Center for Drug Evaluation and Research; 2019. Available from: <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm>. Accessed February 20, 2019.
- Festen DAM, de Lind van Wijngaarden R, van Eekelen M, et al. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. *Clin Endocrinol (Oxf).* 2008;69(3):443-451.
- Finkelstein BS, Imperiale TF, Speroff T, et al. Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis. *Arch Pediatr Adolesc Med.* 2002;156(3):230-240.
- Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2016;101(11):3888-3921.
- Genotropin [package insert]. New York, NY: Pharmacia & Upjohn Co.; December 2016.
- Gravholt CH, Andersen NH, Conway GS, et al; International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. *Eur J Endocrinol.* 2017;177(3):G1-G70.
- Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. *Horm Res Pediatr.* 2016;86:361-397.
- Hazem A, Elamin MB, Bancos I, et al. Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. *Eur J Endocrinol.* 2012;166(1):13-20.
- Hopwood NJ, Hintz RL, Gertner JM, et al. Growth response of children with non-growth-hormone deficiency and marked short stature during three years of growth hormone therapy. *J Pediatr.* 1993;123(2):215-222.
- Humatrope [package insert]. Indianapolis, IN: Eli Lilly and Company; December 2016.
- Jung H, Land C, Nicolay C, et al. Growth response to an individualized vs fixed dose GH treatment in short children born small for gestational age: the OPTIMA study. *Eur J Endocrinol.* 2009;160(2):149-56.
- Ketteler M, Block GA, Evenepoel P, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the Kidney Disease: Improving Global Outcomes 2017 clinical practice guideline update. *Ann Intern Med.* 2018 Feb 20. doi: 10.7326/M17-2640.
- Kriström B, Aronson AS, Dahlgren J, et al. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. *J Clin Endocrinol Metab.* 2009;94(2):483-490.
- Lindgren AC, Hagenas L, Muller J, et al. Effects of growth hormone treatment on growth and body composition in prader-willii syndrome: a preliminary report. The Swedish National Growth Hormone Advisory Group. *Acta Paediatr Suppl.* 1997;423:60-62.
- Lindgren AC, Hagenas L, Muller J, et al. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favorably. *Acta Paediatr.* 1998;87:28-31.
- Lindgren AC, Ritzen EM; Swedish National Growth Hormone Advisory Group. Five years of growth hormone treatment in children with Prader-Willi syndrome. *Acta Paediatr Suppl.* 1999;433:109-111.
- MacGillivray MH, Baptista J, Johanson A. Outcome of a four-year randomized study of daily vs three times weekly somatotropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group. *J Clin Endocrinol Metab.* 1996;81(5):1806-1809.
- Maiorana A, Cianfarani S. Impact of growth hormone therapy on adult height of children born small for gestational age. *Pediatrics.* 2009;124(3):e519-31.
- Massa G, Otten BJ, de Muinck Keizer-Schrama SMPF, et al. Treatment with two growth hormone regimens in girls with Turner syndrome: final height results. *Horm Res.* 1995;43:144-146.
- Mauras N, Attie KM, Reiter EO, et al. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. *J Clin Endocrinol Metab.* 2000;85(10):3653-3660.
- Molitch ME, Clemmons DR, Malozowski S; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96(6):1587-1609.
- Moyle GJ, Daar ES, Gertner JM, et al; Serono 9037 Study Team. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2004;35(4):367-375.

- Myers SE, Carrel AL, Whitman BY, et al. Physical effects of growth hormone treatment in children with Prader-Willi syndrome. *Acta Paediatr.* 1999 (Suppl);433:112-114.
- Myers SE, Whitman BY, Carrel AL, et al. Two years of growth hormone therapy in young children with Prader-Willi syndrome. *Am J Med Genet A.* 2007;143(5):443-448.
- National Kidney Foundation. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. *Am J Kidney Dis.* 2009;53(3 Suppl 2):S11-104.
- Nienhuis HE, Rongen-Westerlaken C, Wit JM, et al. Results of long-term therapy with growth hormone in two dose regimens in Turner Syndrome. *Horm Res.* 1993;39(Suppl 2):31-36.
- Noordam C, van der Burgt I, Sengers RCA, et al. Growth hormone treatment in children with Noonan's syndrome: four year results of a partly controlled trial. *Acta Paediatr.* 2001;90:889-894.
- Noordam C, Peer PG, Francois I, De Schepper J, van den Burgt I, Otten BJ. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. *Eur J Endocrinol.* 2008;159(3):203-208.
- Norditropin Flexpro [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; February 2018.
- Nutropin AQ [package insert]. South San Francisco, CA: Genentech, Inc.; December 2016.
- Omnitrope [package insert]. Princeton, NJ: Sandoz Inc.; December 2016.
- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations [database on the internet]. Silver Spring (MD): Food and Drug Administration (US), Center for Drug Evaluation and Research; 2019. Available at: <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>. Accessed February 20, 2019.
- Pironi L, Arends J, Bozzetti F, et al; Home Artificial Nutrition & Chronic Intestinal Failure Special Interest Group of ESPEN. ESPEN guidelines on chronic intestinal failure in adults. *Clin Nutr.* 2016;35(2):247-307.
- Reed ML, Merriam GR, Kargi AY. Adult growth hormone deficiency – benefits, side effects, and risks of growth hormone replacement. *Front Endocrinol (Lausanne).* 2013;4(64):1-14. doi: 10.3389/fendo.2013.00064
- Rogol AD, Richmond EJ. Treatment of growth hormone deficiency in children. UpToDate Web site. [www.uptodate.com](http://www.uptodate.com). Updated November 3, 2017. Accessed February 20, 2019.
- Romano AA, Dana K, Bakker B, et al. Growth response, near-adult height, and patterns of growth and puberty in patients with Noonan syndrome treated with growth hormone. *J Clin Endocrinol Metab.* 2009;94(7):2338-2344.
- Romer T, Saenger P, Peter F, et al. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study. *Horm Res.* 2009;72(6):359-369.
- Saizen [package insert]. Rockland, MA: EMD Serono Inc.; May 2018.
- Sas TC, de Ridder MA, Wit JM, et al. Adult height in children with growth hormone deficiency: a randomized, controlled, growth hormone dose-response trial. *Horm Res Paediatr.* 2010;74(3):172-181.
- Sas TCJ, De Muinck Keizer-Schrama SMPF, Jansen M, et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. *J Clin Endocrinol Metab.* 1999[a];84(12):4607-4612.
- Sas T, de Waal W, Mulder P, et al. Growth hormone treatment in children with short stature born small for gestational age: five-year results of a randomized, double-blind, dose-response trial. *J Clin Endocrinol Metab.* 1999[b];84(9):3064-3070.
- Schambelan M, Mulligan K, Grunfeld C, et al; Serostim Study Group. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. *Ann Intern Med.* 1996;125(11):873-882.
- Serostim [package insert]. Rockland MA: EMD Serono Inc.; May 2018.
- Shih KC, Ho LT, Kuo HF, et al. Linear growth response to recombinant human growth hormone in children with growth hormone deficiency. *Zhonghua Yi Xue Za Zhi (Taipei).* 1994;54(1):7-13.
- Sklar CA, Antal Z, Chemaitilly W, et al. Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2018;103:2761-2784. doi: 10.1210/je.2018-01175.
- Takano K, Shizume K, Hibi I, et al. Growth hormone treatment in Turner syndrome: results of a multicentre study in Japan. Committee for the Treatment of Turner's Syndrome. *Horm Res.* 1993;39(Suppl 2):37-41.
- Takano K, Shizume K, Hibi I, et al. Long-term effects of growth hormone treatment on height in Turner syndrome: results of a 6-year multicentre study in Japan. Committee for the Treatment of Turner's Syndrome. *Horm Res.* 1995;43:141-143.
- Takano K, Shizume K, Hibi I. Treatment of 80 patients with Turner's syndrome with recombinant human growth hormone (YM-17798) for one year: the results of a multicentric study in Japan. Committee for the Treatment of Turner's Syndrome. *Endocrinol Jpn.* 1989[b];36(2):253-60.
- Takano K, Shizume K, Hibi I. Treatment of 94 patients with Turner's syndrome with recombinant human growth hormone (SM-9500) for two years--the results of a multicentric study in Japan. Committee for the Treatment of Turner's Syndrome. *Endocrinol Jpn.* 1989[c];36(4):569-78.
- Takano K, Shizume K, Hibi I. Turner's syndrome: treatment of 203 patients with recombinant human growth hormone for one year. A multicentre study. *Acta Endocrinol (Copenh).* 1989[a];120(5):559-568.
- van Gool SA, Kamp GA, Odink RJ, et al. High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height. *Eur J Endocrinol.* 2010;162(4):653-660.
- van Pareren YK, de Muinck Keizer-Schrama SMPF, Stijnen T, et al. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. *J Clin Endocrinol Metab.* 2003;88(3):1119-1125.
- van Teunenbroek A, De Muinck Keizer-Schrama SMPF, Stijnen T, et al. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner Syndrome. *J Clin Endocrinol Metab.* 1996;81(11):4013-4021.
- Wales PW, Nasr A, de Silva N, Yamada J. Human growth hormone and glutamine for patients with short bowel syndrome. *Cochrane Database Syst Rev.* 2010;(6):CD006321.
- Wilson DM, Baker B, Hintz RL, Rosenfeld RG. Subcutaneous vs intramuscular growth hormone therapy: growth and acute somatomedin response. *Pediatrics.* 1985;76(3):361-364.
- Wit JM, Rekers-Mombarg LT, Cutler GB, et al. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. *J Pediatr.* 2005;146(1):45-53.
- Zomacton [package insert]. Parsippany, NJ: Ferring Pharmaceuticals, Inc.; July 2018.
- Zorbitive [package insert]. Rockland, MA: EMD Serono, Inc.; May 2017.





Publication Date: February 25, 2019